Levels of lipoprotein(a) [Lp(a)] need to be reduced by substantially more than has been achieved in recent trials
Levels of lipoprotein(a) [LP(a)] need to be reduced substantially in order to have the same impact on coronary heart disease (CHD) risk as that seen with relatively modest reductions of low-density lipoprotein (LDL) cholesterol, suggests a large-scale analysis of trial data.
Source: Medscape
Related stories
- Ketogenic Diet and Lipids
- Low Carbohydrate diets, Weight management, Type 2 diabetes and Dyslipidaemia
- Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia
- Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
- Diagnosis, management and prognosis of familial hypercholesterolaemia in a UK tertiary cardiac centre
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- Does diet quality or nutrient quantity contribute more to health?
- Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
- Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care
- Identifying FH Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors
Go to the main National Cholesterol Month page to find out even more!
Go